STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

  1. Home
  2. Sec-filings
  3. NLSP
  4. [EFFECT] NLS Pharmaceutics Ltd. SEC Filing

[EFFECT] NLS Pharmaceutics Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 18, 2025
Accession Number: 0001213900-25-106799
Submission Type: POS AM
CIK: 0001783036
Company Name: NewcelX Ltd.
File Number: 333-284075

Source: View Original Filing on SEC EDGAR

Stock NLSP logo
Nls Pharmaceutics Ltd

NASDAQ:NLSP

NLSP Rankings

#6659 Ranked by Market Cap
N/A Ranked by Dividends

NLSP Latest News

Nov 17, 2025
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
Oct 30, 2025
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
Oct 29, 2025
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
Oct 29, 2025
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
Oct 29, 2025
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLSP Latest SEC Filings

Nov 19, 2025
[EFFECT] NLS Pharmaceutics Ltd. SEC Filing
Nov 17, 2025
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer)
Nov 7, 2025
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer)
Nov 5, 2025
[POS AM] NLS Pharmaceutics Ltd. SEC Filing
Nov 4, 2025
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer)

NLSP Stock Data

3.97M
3.08M
32.46%
9.81%
0.51%
Biotechnology
Healthcare
Link
Switzerland
Zurich